ARVINAS, INC. Increase (Decrease) in Contract with Customer, Asset
ARVINAS, INC. (ARVN) reported Increase (Decrease) in Contract with Customer, Asset of $26.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2026-08-04
- ARVINAS, INC. increase (decrease) in contract with customer, asset for the quarter ending 2025-12-31 was $0.00.
- ARVINAS, INC. increase (decrease) in contract with customer, asset for the quarter ending 2025-09-30 was $0.00.
- ARVINAS, INC. increase (decrease) in contract with customer, asset for the quarter ending 2024-12-31 was $0.00.
- ARVINAS, INC. increase (decrease) in contract with customer, asset for the quarter ending 2024-09-30 was $0.00.
- ARVINAS, INC. increase (decrease) in contract with customer, asset for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ARVINAS, INC. increase (decrease) in contract with customer, asset for fiscal 2024 was $3.00M.
- ARVINAS, INC. increase (decrease) in contract with customer, asset for fiscal 2023 was $0.00.
- ARVINAS, INC. increase (decrease) in contract with customer, asset for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 6 month | Increase (Decrease) in Contract with Customer, Asset 9 month | Increase (Decrease) in Contract with Customer, Asset 9 month as first filed | Increase (Decrease) in Contract with Customer, Asset 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $26.80M 10-Q · filed 2026-08-04 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-04 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $3.00M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.00M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $3.00M 10-Q · filed 2025-08-06 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $0.00 10-Q · filed 2024-10-30 | |||
| 2023-06-30 | $0.00 10-Q · filed 2024-07-30 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $0.00 10-K · filed 2025-02-11 | |||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $12.90M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $12.90M 10-Q · filed 2022-11-09 | $12.87M 10-Q · filed 2021-11-03 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 10-K · filed 2023-02-23 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-03 | ||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |